AUTHORS
Michelle Lu, N/A, Ryan Han2, Tuisha Gupta, MD3, Fanyuan Zeng, MD4, Zihan Chen, MS5, Jian-Ming Li, MD PhD6, Cynthia Giver, PhD7, Shruti Bhatt, PhD8, Kiranj Chaudagar, Ph.D.9, Ned K. Waller, MD PhD FACP10
AFFILIATIONS
1 Emory University College of Arts and Sciences, Atlanta, Georgia, United States
2 Emory University College of Arts and Sciences, Atlanta, Georgia, United States
3 Emory University School of Medicine, Atlanta, Georgia, United States, Winship Cancer Institute, Atlanta, Georgia, United States
4 Emory University School of Medicine, Atlanta, Georgia, United States
5 Georgia Institute of Technology, Atlanta, Georgia, United States
6 Emory University School of Medicine, Atlanta, Georgia, United States, Winship Cancer Institute, Atlanta, Georgia, United States
7 Emory University School of Medicine, Atlanta, Georgia, United States, Winship Cancer Institute, Atlanta, Georgia, United States
8 Emory University School of Medicine, Atlanta, Georgia, United States, Winship Cancer Institute, Atlanta, Georgia, United States
9 Emory University School of Medicine, Atlanta, Georgia, United States, Winship Cancer Institute, Atlanta, Georgia, United States
10 Emory University School of Medicine, Atlanta, Georgia, United States, Winship Cancer Institute, Atlanta, Georgia, United States
ABSTRACT
Background
TP53-mutant acute myeloid leukemia (AML) represents one of the highest-risk subtypes, with a median overall survival of <6-months despite chemotherapy or venetoclax/azacitidine (VEN/AZA). Immune checkpoint inhibitors targeting PD-1 or CD47 have shown limited clinical benefit, suggesting that alternative immune suppressive mechanisms govern disease persistence. We hypothesized that vasoactive intestinal peptide (VIP) signaling establishes a macrophage-centered immune checkpoint that promotes immune escape and therapeutic resistance in TP53-mutant AML.
Methods
Transcriptomic datasets from AML patients were interrogated to define TP53-associated immune regulatory pathways and correlate VIP/VPAC-signaling with clinical outcomes. Peripheral blood and bone marrow mononuclear cells from 40 AML patients, including 11 TP53-mutant cases, were analyzed by multiparameter flow cytometry to determine the cellular source of VIP and receptor expression. TP53-isogenic AML cell lines were treated with VEN (3nM) and azacitidine (50nM) for 24-hours, and VIP secretion was quantified by ELISA. Macrophage polarization, IL-12 production, and phagocytosis of leukemic blasts by macrophages were evaluated using murine and human macrophage co-culture assays. Therapeutic efficacy of the first-in-class VPAC antagonist, ANT308, was assessed alone and in combination with VEN/AZA or cytarabine in AML models.
Results
Unbiased transcriptomic analysis identified VIP as one of the most significantly upregulated immune regulatory genes in TP53-mutant AML, whereas canonical immune checkpoints including PD-1 and CD47 were not significantly altered (VIP log2FC =1.2, p<0.001). High VPAC1 expression was associated with inferior overall survival specifically in TP53-mutant AML (p<0.01).
Flow cytometric analyses demonstrated that leukemic blasts were the predominant cellular source of VIP, with ~55% (6/11) of TP53-mutant AML specimens exhibiting elevated VIP expression compared with levels expressed by monocytes from healthy volunteers (2.2-fold increase). The frequency of VIP expression among blasts ranged from 10–100%, indicating substantial interpatient heterogeneity. TP53-loss increased VIP secretion by >3-fold, while VEN/AZA further enhanced secretion by 200%, demonstrating that standard therapy amplifies this immunosuppressive pathway.
Mechanistically, VPAC1 was preferentially expressed on macrophages, whereas VPAC2 expression remained minimal. Genetic ablation or pharmacologic inhibition of VIP signaling increased IL-12 production by M2-like macrophages by 1.5-fold (p<0.05) without affecting inflammatory macrophages. TP53-mutant high-VIP leukemia cells demonstrated ~50% lower phagocytosis by macrophages than TP53-wildtype controls (p<0.05). Conversely, VPAC blockade with ANT308 increased macrophage-mediated leukemia phagocytosis by ~2-fold and restored anti-leukemia immune activity.
Collectively, these findings identify a persistent VIP-high leukemia cell state that limits the phagocytic activity of macrophages, is augmented by TP53-mutation and further amplified following chemotherapeutic stress, thereby establishing a feed-forward macrophage immune checkpoint that promotes leukemia persistence and relapse.
Conclusions
We identify blast-derived VIP as a previously unrecognized macrophage immune checkpoint linking TP53-mutation with therapy-induced immune escape in AML. TP53-mutations not only enhance leukemia cell survival but actively remodel the innate immune microenvironment through the VIP-VPAC1 axis, suppressing macrophage phagocytosis and IL-12-dependent adaptive immune priming. Pharmacologic VPAC blockade reverses this suppressive circuit, restores anti-leukemia immunity, and enhances therapeutic efficacy, establishing the VIP-VPAC1 pathway as a promising biomarker and immunotherapeutic target for high-risk TP53-mutant AML.
DISCLOSURES
Michelle Lu, N/A: No relevant conflicts of interest to declare.